# Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

> **NCT06084897** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 120 (estimated)

## Conditions studied

- Esophageal Neoplasm Metastatic
- Esophageal Cancer Stage IVb

## Interventions

- **DRUG:** TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
- **BIOLOGICAL:** PD-1 inhibitor
- **RADIATION:** Consolidation Radiation
- **RADIATION:** Salvage Radiation

## Key facts

- **NCT ID:** NCT06084897
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-16
- **Primary completion:** 2026-04-26
- **Final completion:** 2028-10-26
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084897, "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06084897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*